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Abstract: Alteration of antigen recognition by T cells as result of insufficient
major histocompatibility complex (MHC)-dependent antigen-presenting
function has been observed in many cases of infections, particularly in in vitro
systems. To hide themselves from an efficient immune response, pathogens
may act on MHC-related functions at three levels: (i) by limiting the number of
potential antigens that can be presented to naı¨ve T cells; (ii) by synthesizing
proteins which directly affect MHC cell-surface expression; and (iii) by altering
the normal intracellular pathway of peptide loading on MHC. Here, we review
examples of pathogens’ action on each single step of MHC function and we
suggest that the result of these often synergistic actions is both a limitation of
the priming of naı¨ve T cells and, more importantly, a protection of the
pathogen’s reservoir from the attack of primed T cells. The above mechanisms
may also generate a skewing effect on immune effector mechanisms, which
helps preserving the reservoir of infection from sterilization by the immune
system.
In medical practice, it is frequently observed that an infectious
disease, effectively controlled at clinical level, is not fully controlled
at microbiological level because the infectious agent cannot be
eradicated by the combined action of therapeutic treatment and
immune response. The potential of some microbes to persist endlessly
in the host is a dramatic evidence of the accomplishment of strategies
to elude the immune response. Apparently, no particular phase or arm
of the vertebrate immune response is entirely safe from pathogen-
evasion strategies. Indeed, microbes exhibit an extremely sophistica-
ted biotechnological skill in the interactions with the host (1). In
particular, in vitro analysis of host–pathogen interactions has
revealed a plethora of alterations affecting both the expression and
the function of major histocompatibility complex (MHC) molecules,
the cell-surface receptors which bind and present antigenic peptides
to T lymphocytes. MHC class I molecules, expressed on virtually all
nucleated cells, bind peptides from endogenously synthesized
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proteins and present them to CD8þ T cells (cytolytic T lymphocytes
or CTL); MHC class II molecules, expressed on few cell types, defined
antigen-presenting cells (APC), bind peptides derived from interna-
lized exogenous proteins, and present them to CD4þ T-helper (Th)
cells. Triggering of Th cells is necessary to initiate the immune
effector mechanisms leading to both cellular (CTL) and humoral
(antibody) responses (2).
Pathogens and MHC
Many viruses possess genes whose products seriously impair MHC-I
expression in infected cells. Remarkably, impaired MHC-I expression
and/or function may be related, in a Mendelean fashion, to the action
of the product of single viral open-reading frames (ORFs) (3).
Following the terminology introduced by Reddehase (4), we will
refer to these genes or gene products as MHC-I immunoevasins.
Bacteria, instead, with few exceptions (5) do not usually impair
MHC function by downregulating MHC-I expression. In some
cases, bacterial infection may actually result in MHC-I upregulation.
For example, we have observed an increase in surface MHC-I mol-
ecules in macrophage phagocytosing a broad range of bacteria (6; A.
De Lerma Barbaro, unpublished data). This overexpression is not
related to a direct effect of the infectious particle or to soluble
substances (toxins) of microbial origin; instead, it is the result of
autocrine factors produced by the cell itself.
In sharp contrast to MHC-I, MHC-II pathway can be altered by a
wide array of pathogens including viruses, intracellular, and extra-
cellular bacteria as well as protozoa and multicellular parasites
(3–14). Given the role of MHC-II molecules in triggering the Th
cells, impairment of MHC-II function would be a major goal for
most pathogens as it would block all the effector arms of the immune
system. With few exceptions (10–15), little is known on pathogen’s
gene products involved in MHC-II dysregulation, and the identity of
most MHC-II immunoevasins remains elusive.
Infectious agents may assail the integrity of MHC function by
different routes. This is related to the fact that the MHC/peptide
complexes are involved at various levels and at different time points
during the generation of an acquired immune response. They are
involved in the priming of naı¨ve T cells, in the identification of the
pathogen reservoir, and in the regulation of immune response
(Fig. 1).
Priming of naı¨ve T cells and identification of the reservoir of
infection pertain to both MHC-I- and MHC-II-related functions. The
‘regulatory’ function of MHC during immune response, still rather ill
defined, involves mostly the MHC-II molecules.
Pathogens’ strategies to limit and/or elude
priming of naı¨ve T cells
It is intriguing that primary T-cell responses against pathogens are
often directed against a small number of pathogens’ gene products (16).
A clear picture of the cellular and molecular events leading to the above
phenomenon is still incomplete. Nevertheless, a series of findings point
to the important role of dendritic cells (DCs) and their MHC molecules.
DCs are the main APCs for priming naı¨ve T cells. DC engulf the
antigen in the periphery, process it, and become functionally mature
while migrating to secondary lymphoid organs where they meet and
stimulate T cells (17). It has been found that some viruses can
provoke a functional paralysis of DC maturation (18). Furthermore,
certain viruses encode ORFs whose products directly affect the
MHC-I expression pathway. It is likely that the above events can
produce a restriction in the number of pathogen’s products effec-
tively available for priming (19).
Herpesviruses are an attractive model system to elucidate the
hypothesis of impaired priming of naı¨ve T cells by means of MHC-
I deregulation. The repertoire of epitopes recognized by MHC-I-
restricted CTLs derived from proteins of HSV, a g-herpesvirus,
HCMV, an a-herpesvirus, EBV, a b-herpesvirus, and the influenza
A virus, are presented in Table 1. Although the HSV-2 genome
encode about 85 polypeptides (20), CTL responses seem to be focused
on only few proteins. In particular, CD8þ T-cell clones infiltrating
genital HSV-2 lesions (21) consistently recognize only one immediate
early (IE) gene product, ICP0, and two late (L) gene products (UL47
and UL49). Likewise, in C57BL/6 mice, infection with HSV-1 elicits a
CTL response that is directed almost entirely to an immunodominant
epitope of gB (gB498505) (22). Human CMV is a virus that encodes
more than 200 polypeptides (20). A series of studies have identified
only a small number of CMV antigens recognized by CTLs. These
include the virion protein pp65 and the major IE protein IE-1 (4).
Although recent analyses conducted by sophisticated detection
systems (23, 24) revealed that the spectrum of epitopes from
HCMV proteins capable to be recognized in vivo by CD8þ CTL is
broader than previously thought, still the number of HCMV proteins
effectively recognizable is very restricted compared to the 200
proteins made by the virus. In particular, an analysis conducted by
a combined algorithm-based searching for MHC-I-binding epitopes
and ex vivo assessment of CD8þ T cells in healthy seropositive
individuals showed the existence of memory T cells for eight distinct
proteins of HCMV. Interestingly, the hierarchy and immuno-
dominance of viral protein-specific CTLs was again in favor of
epitopes in the previously recognized pp65 and IE-1 viral proteins
(23). As a matter of fact, both HSV and CMV herpesviruses
productively infect DCs, causing in these cells an impairment in
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antigen-presentation capacity (25, 26), and both herpesvirus
encode the most efficient inhibitors of MHC-I pathway described so
far (3).
On the contrary, the CD8þ CTL repertoire against the proteoma of
both influenza A virus and EBV is broad. During human flu infec-
tions, it is possible to find CTL responses directed against six of the
10 proteins encoded by the virus (27). In mice, a wide-ranging
analysis of antigenic peptides from influenza A PR8 strain proteome
has shown CTL responses directed against 10 of the 11 viral pro-
ducts (28). Similar findings have been described for EBV infections:
among six viral products analyzed, two IE antigens and three E
antigens elicit CD8þ T responses (29). These two viruses do not
interfere directly with the MHC-I pathway, although the EBNA from
EBV impairs its own proteasome-mediated degradation preventing
formation of peptides that may be bound by MHC-I molecules (30).
Importantly, both influenza virus and EBV do not inhibit functional
maturation of DC (31, 32).
The correlations summarized in Table 1 offer the hint for an
additional consideration related to the availability and immunogeni-
city of a viral antigen. A narrowed CTL response against pathogen’s
products can be observed for viruses that bear MHC-I immuno-
evasins. ICP47 from HSV and the products of the US2-US11 gene
region of HCMV strongly downregulate MHC-I cell-surface expres-
sion (3). Thus, potentially immunogenic peptides from proteins that
during the life cycle of the two viruses are synthesized downstream
of the ICP47 and US2-US11 immunoevasins, respectively, may have
an objective difficulty in being presented by MHC-I molecules of the
infected DCs. The host, however, can still counteract the effect of
immunoevasins in several ways: the APCs that can be infected may
be diverse and thus display a different susceptibility to the action of
immunoevasins (23, 24, 33); the action of immunoevasins can be
overcome by the capacity of uninfected APCs to cross-present viral
antigens that cannot be presented by infected cells (34); lastly,
immunoevasins may have different inhibitory potential on MHC-I
function and/or expression depending upon the MHC-I allele present
in the infected host (35).
Identification of the cellular reservoir of
infection
It has been argued that the goal of intracellular pathogens is not to
kill the cell host, but to replicate and spread to an extent compatible
with survival of both pathogen and host. Therefore, the maintenance
of a cellular reservoir (Fig. 1B) can be considered a priority for
pathogens. Experimental evidence documents in many cases disrup-
tion of the MHC-II pathway by intracellular pathogens in the
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Fig. 1. Major histocompatibility complex (MHC) drives acquired
immune response acting on three phases. MHC class I (MHC-I) mol-
ecules are expressed on virtually all cells. MHC class II (MHC-II) molecules
are constitutively expressed on few cell types such as dendritic cells (DCs), B
cells, and macrophages; however, their expression can be induced in many
cell types, particularly during inflammation generated by pathogen infection.
Here, MHC-I and MHC-II molecules are depicted with a unique symbol. MHC
molecules act on three levels of the immune response against pathogens. (A)
They bind antigenic peptides ( ) derived from pathogens’ proteins and
present them to virgin naı¨ve T cells (Tn) (CD4 and CD8) for priming. The
priming function is mainly carried out by DCs, which are considered the
prototype of professional antigen-presenting cells. (B) MHC molecules
expressed on infected cells present pathogen-derived peptides to primed T
cells (Tp) and help the immune effector cells to attack and eliminate the
pathogen’s reservoir of infection. (C) MHC molecules, particularly MHC-II
molecules, may regulate the immune response by acting both on the priming
and on the functional maturation of polarized forms of T-helper (Th) cells, as
Th-1 and Th-2 cells. This may be achieved by the alternative or preferential
usage of recycling vs newly synthesized MHC-II molecules which are loaded
with distinct antigenic peptides ( , ). T-cell recognition of the distinct
MHC-II-peptide complexes can generate a different pattern of effector cell
response depicted in the figure as the secretion of alternative cytokines. TcR,
T-cell receptor.
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reservoir of infection (3–5, 7, 8, 36). Thus, if the infected cells can
function as surrogate APCs, an inhibitory action on the MHC-II
pathway could be particularly useful to intracellular bacteria and
protozoa (whose antigens are presented mainly by MHC-II) for over-
coming sterilization of the reservoir mediated by primed Th cells
(Fig. 2). In fact, these cells need recognition of MHC-II–peptide com-
plex to be stimulated but have less requirements than naı¨ve T cells
for accessory costimuli (14, 37). Within this frame, it should be
stressed that pathogen-mediated MHC-II downregulation in APCs
may affect a major effector function of Th-1 cells, the production of
interferon-gamma (IFN-g), whose microbicidal activity within the
reservoir of infection has been firmly established (38).
In the course of viral infections, analogous circumstances could
also take place. Presentation of non-viable virions via MHC-II and its
relevance to the help of B lymphocytes and CTL have been well
documented (14). Moreover, viral antigens can be loaded on MHC-II
also in productively infected cells; in fact, viral structural proteins
move to the endosomal compartment, presumably during the bud-
ding of infective particles. In this compartment, viral peptides can be
bound by MHC-II molecules, either newly synthesized or recycling
from the cell surface (8, 39), and be expressed on the cell surface
where they can be recognized by CD4þ T cells. These T cells can
mediate a direct sterilization of the reservoir of infection through an
intrinsic cytotoxic function (40), or through secretion of cytokines
that enhance cellular antiviral function. For instance, IFN-g induces
expression of 20,50-oligoadenlyate synthetase that mediates degrada-
tion of viral RNA (41). Therefore, viruses could improve their fitness
by interfering with MHC-II-presentation pathways in productively
infected cells as well.
The strategy for improving the fitness of a pathogen for the host
can be exerted also in another way. In macrophages undergoing
bacterial phagocytosis, the reservoir of infection is an heterogeneous
population in which single cells could contain very different patho-
gen loads, and we have observed an inverse correlation between
MHC-II expression and bacterial burden in vitro (A. De Lerma
Barbaro, unpublished data). From the pathogen’s side, to achieve
an enhanced fitness and to establish a hidden reservoir protected
from immune attack, it could be sufficient to escape Th-mediated
sterilization in only few cells among those infected (Fig. 2). Studies
devoted to the analysis of MHC-II downmodulation in biopsy speci-
mens of infected tissues, such as those reported for CMV-infected
lung tissues (42), could be extremely useful in clarifying the impor-
tance of the differential pathogen load for the establishment of a
persistent infection. Within this frame, the additional inhibitory
effect on MHC-II exerted not only on the infected cells but also on
bystander APCs by certain viruses that induce the production, or
code for a homolog, of the MHC-II-inhibitory cytokine IL-10 (43)
should be also considered.
Correlation between viral infection of dendritic cells (DCs), their antigen-presenting cell (APC) function, and MHC-I-restricted response of immune cytolytic T
lymphocytes (CTL) effector cells
Virus Genes that affect MHC-I pathway Interaction with DCs CD8þ T-cell epitopes identified
Herpes simplex virus ICP-47 (3, 36) Infection of DC causes inhibition of T-cell-
stimulatory capacity (25)
Human: three IE and four L products (21)
Mouse: mainly focused to the gB L product (22)
Viral genome encodes 85 proteins
Cytomegalovirus US2, US3, US6, US11, US18,
m04, m06, m152 (4, 36)
Infection of DC causes downregulation of
MHC molecules and reduced
antigen-presentation capacity (26)
Human: dominant for one L gene encoding pp65
and for one IE gene encoding UL123 (4, 19);
detectable for L gene products pp50,
p150, pp28, gB (23)
Mouse: one IE and six E/L products (4)
Viral genome encodes >200 proteins
Epstein–Barr virus EBNA-1 (30) Infection induces apoptosis in precursor
monocytes but not in DCs (32)
Two IE and three E gene products
among eight viral proteins tested (29)
Viral genome encodes >80 lytic cycle products
Influenza A virus Unknown Infection causes DC maturation and
release of IL-12 (31)
Human: six viral products (27)
Viral genome encodes only 10 proteins
Mouse: 10 viral products (28)
Viral genome encodes only eleven proteins
Table 1
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The assertions made for MHC-II may likely apply to MHC-I as
well. Indeed, viruses would increase their fitness if they can protect
the reservoir of infection from sterilization by MHC-I-restricted CTL
effectors, as it has been shown during Kaposi herpes virus (KSHV)
infection (44). If from one side, MHC-I downmodulation would pro-
tect infected cells from CTL recognition, from the other side these
cells may become potential target of natural killer (NK)-mediated
lysis. It is of relevance that also against NK attack, the KSHV virus
has developed counteracting mechanisms by synthesizing the K5
protein which inhibit both MHC-I expression and NK-mediated cyto-
toxicity (45). Some viral pathogens have developed strategies for
escaping MHC-mediated recognition and creating a hidden reservoir
that rely on limiting the number of potential antigenic peptides
recognizable by effector CTLs. For example, the occurrence of
frequent spontaneous genomic mutations during infections by lenti-
viruses, such as HIV and SIV (46, 47), may generate mutant peptides
that no longer bind, or bind with reduced affinity, to MHC-I molecules
(48); alternatively, the mutation can affect the processing of mutant
protein leading to an impaired trimming of the peptide (49).
Regulatory function of MHC/peptide
complex
It is becoming apparent that the MHC–antigen peptide complex
plays an important role not only on the efficacy but also on the
quality of T-cell stimulation. Some data support the view that pep-
tide loading onto recycling vs newly synthesized MHC-II molecules
may produce conformationally distinct complexes distinguishable by
TcRs (50, 51) (Fig. 1C). Epitopes loaded on recycling MHC-II are
often located on structurally simple, non-globular domains of the
protein (52, 53). For example, immunization with reduced and alky-
lated MSP-1 from malaria merozoide allows C-terminal region,
usually loaded on newly synthesized MHC-II, to be presented by
recycling MHC-II (52). More recent data suggest that mild acidifica-
tion and disulfide bond reduction of influenza hemagglutinin, in the
absence of proteolysis, provides sufficient processing for loading on
recycling MHC-II (54), confirming previous observations that an
entire protein subunit may indeed be loaded on recycling MHC-II
(55). Moreover, it has been shown that VacA from Helicobacter pylori
specifically inhibits the Ii-dependent pathway of antigen presenta-
tion on newly synthesized MHC-II molecules, leaving unaffected the
Ii-independent pathway on recycling MHC-II (10). Bm-CPI-2, a
cysteine protease inhibitor from Brugia malayi, displays remarkable
similarities with VacA as a suppressor of MHC-II presentation (11).
Taken together, all the above observations strongly suggest that
redirection of peptide loading on recycling MHC-II molecules may
substantially change the repertoire of peptide antigens which can be
presented to T cells. At the same time, this event can generate a
qualitatively different hierarchy in the T-cell clones involved in the
immune effector function. One possible skewing effect can be a
biased Th-1/Th-2 polarization (56). The selective advantage of the
pathogen would consist in redirecting the course of acquired immu-
nity toward a non-protective response rather than in avoiding recog-
nition. A plausible link of these speculations to the clinics would be
the observation that the immunopathological sequelae of H. pylori
infection may consist in an autoimmune syndrome characterized by
a Th-1 profile (57).
Conclusions and future perspectives
Interference of infectious agents on the MHC-I and MHC-II pathways
may play a relevant role in vivo not only in preventing T-cell priming
but, more importantly, in hiding and protecting the cellular reser-
voirs of infection from sterilization. Future studies focused on the
connection between molecular aspects (i.e., ORFs that impair MHC
function), and cellular events (the interaction between the pathogen
and the APC, as well as the T-cell repertoire effectively stimulated)
will be instrumental to better clarify host–pathogen interaction dur-
ing infectious diseases.
Moreover, it will be of paramount importance to elucidate the role
of ‘ectopic’ expression of MHC-II in vivo in non-professional APCs
Tp
Tp
Tp
Tp Tp
Tp
TpTp
Tp
TcR
MHC
Fig. 2. Inverse correlation between pathogen load and major his-
tocompatibility complex (MHC) expression. Downregulation of MHC
expression induced by pathogens ( ) has been shown in many cases of viral
and bacterial infections. At the single cell level, the intensity of the MHC
downregulation correlates with the intracellular pathogen load. This, in turn,
can generate a differential response of primed immune effector T cells (Tp)
against the infected cells, resulting in the preferential elimination of those
cells with a low pathogen load. Thus, the persistence of infection despite an
active and performant immune response, may increase the fitness of the
pathogen and generate, by a vicious circle, a skewing of the immune response
toward a non-protective immunity. TcR, T cell receptor.
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that can be reservoir of intracellular pathogens. Within this frame,
more emphasis should be given to the identification of MHC-II
immunoevasins. HCMV encodes the three major viral MHC-II immu-
noevasins identified to date, namely U2, U11, and U3, and it is
interesting to note that these molecules affect MHC-I pathway as
well. Unfortunately, since a suitable animal model for HCMV infec-
tion is lacking, it is not possible to study the in vivo relevance of
these genes by deletion analysis (58). Microbes bearing a transgenic
GFP (59) can be used to identify infectious particles in tissues, the
relative pathogen load in cells of the affected tissue, and the corre-
sponding expression of MHC-II molecules. The targeted inactivation
of the promoter IV of the AIR-1 gene encoding the MHC-II transacti-
vator (CIITA) (60, 61) produces mice whose putative APCs of
non-hematopietic origin cannot be induced by IFN-g for MHC-II
expression (62). These mice could be a valuable in vivo model to
study the relevance of MHC-II inducibility in the clinical course of
infections by some intracellular pathogens such as chlamydia,
salmonella, and CMV that colonize cellular reservoirs distinct from
macrophages.
These studies will increase the knowledge of the pathogen–host
interactions and will contribute to the design of novel strategies for
vaccine production.
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